Calaprice Denise, Tona Janice, Murphy Tanya K
1 Calaprice-Whitty Consulting, Inc. , Lake Arrowhead, California.
2 Department of Rehabilitation Science, University at Buffalo , Buffalo, New York.
J Child Adolesc Psychopharmacol. 2018 Mar;28(2):92-103. doi: 10.1089/cap.2017.0101. Epub 2017 Aug 23.
The goal of this study was to investigate treatment histories and outcomes in a large community sample of youth with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), and, where appropriate, to examine the impact of immune deficiency on treatment outcomes.
A comprehensive internet-based survey was completed by parents or guardians of youth who had received physician diagnoses of PANS, or by young adults (age 18+) who had themselves been diagnosed by a physician (N = 698). Data regarding the treatment histories of these patients, including the variety of medical and psychological treatments employed and the caregiver- or self-reported response to each, are presented.
The PANS patients in this study had commonly been treated with antibiotic (N = 675), anti-inflammatory (N = 437), and/or psychotropic therapy (N = 378). Response to antibiotic treatment was best when treatment was relatively aggressive, with broad-spectrum antibiotics and courses of >30 days generally producing the best results (i.e., up to 52% of patients achieving a "very effective" response). For immune-deficient patients (caregiver-reported laboratory studies below normal limits; N = 108), use of broad-spectrum antibiotics appeared to be particularly desirable. Anti-inflammatory therapies, including over-the-counter medications such as ibuprofen, were at least "somewhat effective" for most patients. Intravenous immunoglobulin (IVIG) had been used to treat PANS in 193 (28%) of the patients and was at least "somewhat effective" for 89%, although for 18% of these, the effect was not sustained. The highest rate of sustained response to IVIG treatment was seen in immune-deficient patients who received doses of at least 0.8 g/kg IVIG on a regular basis. Psychotropic medications, most commonly SSRIs (38% reported a trial), were commonly employed, but were often ineffective (e.g., 44% found SSRIs "somewhat" to "very effective"). Many patients (N = 473) had received some form of psychotherapy with some benefit, with cognitive behavioral therapy found to be at least somewhat effective in a majority of those treated with this modality.
Among the PANS patients represented in this study, relatively aggressive treatment courses targeted at eradicating infection and modulating the inflammatory response appeared to provide the best caregiver-reported therapeutic results, and to be generally well tolerated. Given its relative efficacy and tolerability, treatment targeting the inflammatory response may represent an underutilized approach in this population. The results of this study should be considered in light of the limitations inherent in a self-selected and administered online survey.
本研究旨在调查患有儿童急性起病神经精神综合征(PANS)的大量社区青少年样本的治疗史及治疗结果,并在适当情况下,研究免疫缺陷对治疗结果的影响。
由已接受医生诊断为PANS的青少年的父母或监护人,或由已被医生诊断的18岁及以上的年轻人完成一项基于互联网的综合调查(N = 698)。呈现了这些患者的治疗史数据,包括所采用的各种医学和心理治疗方法以及照顾者或自我报告的对每种治疗的反应。
本研究中的PANS患者通常接受过抗生素治疗(N = 675)、抗炎治疗(N = 437)和/或精神药物治疗(N = 378)。当治疗相对积极时,抗生素治疗的反应最佳,使用广谱抗生素且疗程超过30天通常能产生最佳效果(即高达52%的患者获得“非常有效”的反应)。对于免疫缺陷患者(照顾者报告的实验室检查低于正常范围;N = 108),使用广谱抗生素似乎特别合适。抗炎治疗,包括布洛芬等非处方药物,对大多数患者至少“有些效果”。193名(28%)患者使用静脉注射免疫球蛋白(IVIG)治疗PANS,其中89%至少“有些效果”,尽管其中18%的效果未持续。在定期接受至少0.8g/kg IVIG剂量的免疫缺陷患者中,IVIG治疗的持续反应率最高。精神药物,最常见的是选择性5-羟色胺再摄取抑制剂(38%报告曾试用),虽常用但往往无效(例如,44%的人认为选择性5-羟色胺再摄取抑制剂“有些”到“非常有效”)。许多患者(N = 473)接受过某种形式的心理治疗并有所受益,认知行为疗法在大多数接受该疗法的患者中至少有些效果。
在本研究中的PANS患者中,针对根除感染和调节炎症反应的相对积极的治疗疗程似乎能提供照顾者报告的最佳治疗效果,且总体耐受性良好。鉴于其相对疗效和耐受性,针对炎症反应的治疗可能是该人群中未充分利用的方法。本研究结果应结合自我选择和自行管理的在线调查所固有的局限性来考虑。